


Cite this: *RSC Adv.*, 2024, 14, 37286

# Modulation of miR-205 expression using a *Cheiranthus cheiri* phyto-nano hybrid as a potential therapeutic agent against breast cancer

Fatima Razzaq,<sup>†a</sup> Samiah Shahid <sup>†\*ab</sup> and Wajeehah Shahid <sup>c</sup>

Breast cancer is the fifth major cause of fatalities associated with cancer worldwide and in Pakistan, 34 066 female breast cancer cases were recorded in 2018. This study was designed to understand extracts of *Cheiranthus cheiri* (*C. cheiri*) and to evaluate the epigenetic modulation of microRNA expression for breast cancer therapy using a selected phyto-nanohybrid treatment. The phytochemical screening revealed the presence of potential phytochemicals and antioxidant scavenging activity in the *C. cheiri* extracts with a DPPH (2-diphenyl-1-picryl-hydroxyl) assay giving an  $IC_{50}$  value of  $20.63 \mu\text{g mL}^{-1}$ . GC-MS (gas chromatography-mass spectroscopy) analysis of the *C. cheiri* *n*-hexane extract detected 42 phytocompounds. Titanium oxide ( $TiO_2$ ) nanoparticles were synthesized and characterized using XRD (X-ray diffraction), SEM (scanning electron microscopy) and EDX (energy dispersive X-ray spectrometry) to confirm the synthesis of anatase (tetragonal)  $TiO_2$ . The prepared nanoparticles were conjugated with the selected plant *i.e.*, *C. cheiri*. The resulting phyto-nanohybrid was used for the subsequent treatment of breast cancer induced in a female rat model. The treatment groups were as follows: doxorubicin as the standard treatment, *C. cheiri*,  $TiO_2$  and the phyto-nano hybrid treatment. After 8 weeks of treatment, the groups induced to exhibit breast cancer (with and without treatment) and the control groups were dissected and analysed for histopathological, haematological and microRNA expression. Histopathological examination revealed chronic inflammation in the dilated ducts and tumour embolus formation, thus confirming the presence of breast cancer in the DMBA-induced female rat model. MicroRNA expression analysis showed a statistically significant decrease in levels of miR-205 in the plasma of the breast cancer rat model compared to the control ( $p < 0.05$ ). After treatment with the phyto-nano hybrid, a statistically significant increase in the expression of miR-205 was observed in the rat models induced to exhibit breast cancer compared to the rat model without any treatment ( $p < 0.05$ ). The downregulation of miR-205 in the plasma of the breast cancer exhibiting model, as compared to the control, and its upregulation after treatment with the selected phyto-nano hybrid indicated its diagnostic and prognostic significance. It is concluded that the phyto-nano hybrid used in this study is effective against breast cancer induced female rat model. All the results support the finding that the selected phyto-nano hybrid has great potential as a possible therapeutic agent for the treatment of breast cancer.

Received 25th April 2024  
Accepted 13th August 2024

DOI: 10.1039/d4ra03069a

rsc.li/rsc-advances

## 1 Introduction

Breast cancer is a leading cause of death nationally in the 21st century, after cardiovascular diseases and skin cancer, in the United States.<sup>1</sup> During 2020, 19 million new cases of breast cancer were recorded in all ages of Pakistani females, and 25

838 people died of breast cancer.<sup>2</sup> Breast cancer rates are high in Asia and particularly in Pakistan. In 2020, one woman in 9 became a breast cancer patient at some stage of their life.<sup>3</sup> Studies have reported 45 genes in the human breast cancer panel and the most common hereditary genes are *BRCA1* and *BRCA2*, whilst some other genes, such as *PALB2*, *PTEN* and *TP53*, are linked with an increased risk of breast cancer.<sup>4</sup> Multiple therapies exist for breast cancer; however, breast cancer can develop resistance to chemotherapy, radiation, and hormonal treatments. These conventional treatments for breast cancer are linked to severe side effects, the development of drug resistance, and the possibility of cancer recurrence. Many research findings indicate that medicinal plants have the potential to have therapeutic benefits.<sup>5</sup>

<sup>a</sup>Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan. E-mail: samiah.shahid@yahoo.com

<sup>b</sup>Research Centre for Health Sciences (RCHS), The University of Lahore, Lahore, Pakistan

<sup>c</sup>Department of Physics, The University of Lahore, Lahore, Pakistan

<sup>†</sup> The first two authors, Fatima Razzaq and Samiah Shahid, have contributed equally to this study and will be considered as first authors.


The bioactive chemicals present in medicinal plants have proven to be valuable for their therapeutic properties and their potential in pharmacological treatments for malignant tumours. Flavonoids and polyphenols that have been derived from plants are synthetic antioxidants which frequently act as chemotherapeutic agents. In addition, antioxidants protect cells from reactive oxygen species and limit the oxidative damage to an organism's cells, thus effectively reducing hazardous degenerative disorders.<sup>4</sup>

*C. cheiri* is a medicinal plant belongs to the *Brassicaceae* family and is a tonic, diuretic, aphrodisiac and expectorant that is useful in dry bronchitis, paralysis and cancer.<sup>6</sup> Bioactive components of plant phenols, cardiac steroids, isothiocyanates and flavonoids have high anti-cancer, anti-inflammatory and antioxidant activity.<sup>7</sup> The essential oils of *C. cheiri* were identified by GC-MS analysis, and were found to be  $\gamma$ -tocopherol,  $\beta$ -tocopherol, campesterol,  $\gamma$ -sitosterol, estragole, carnosic acid, gamma muurolene,  $\beta$ -sitosterol and delta cadinol. Different studies have identified plant components as being modulators of miRNA expression in different types of cancer. An effective approach while dealing with miRNA regulation involves utilizing a natural plant source as it will be cost-effective and safe.<sup>8</sup>

MicroRNAs can be used as non-invasive diagnostic tools and prognostic biomarkers for cancer. Traditional targeted therapies can cause adverse side effects, drug resistance and can be ineffective for the treatment of metastasis so there is a need to explore some new strategies, such as microRNA based therapies, which can evaluate alterations in oncogenic microRNA expression.<sup>9</sup> Because of their ability to regulate microRNAs, plant-based products or their synthetic analogues have recently gained attention as a potential cancer prevention treatments. The modification of specific miRNA responses was aided by plant compounds such as artemisinin, curcumin, isoflavones, diindolylmethane (DIM), indole-3-carbinol (I3C), and epigallocatechin gallate (EGCG). The modified miRNA expression boosts the sensitivity of the cancer cells to conventional medicines, hence limiting tumour growth. It is reported that changing miRNA regulation could provide a new approach for developing an effective cancer therapy method.<sup>10</sup>

Understanding the potential of plant products and miRNAs for the breast cancer prevention and treatment in low-income populations is of paramount importance, given that evidence suggests that this illness is a result of health inequality. Therefore breast cancer can be prevented and treated with the use of natural medicines or their derivatives, either in isolation or in conjunction with traditional medicine.<sup>11</sup> In this research the role of plant-mediated regulation of miRNAs in breast cancer prevention and treatment was evaluated. Understanding the anti-breast-cancer drug response mechanism can be aided by discussing the interactions with miRNA and their targeted genes. By altering miRNA expression and tumour suppressor genes, and by targeting oncogenes, natural medicines selectively inhibit malignant cells.<sup>12</sup>

MicroRNA expression can be modulated by nanoparticles and they represent an effective approach to drug delivery for the

treatment of many disorders. Nanotechnology may have remarkable potential to prevent breast cancer recurrence. Nanoparticle drug delivery systems are currently emerging and nanoparticles are a renewable material and chemotherapeutic drug in breast cancer models. Different nanoparticles, such as zinc-oxide and selenium nanoparticles, prevent the growth of mammary tumours<sup>10</sup> whilst some other metal-based or magnetic nanoparticles are used for metastatic breast cancer detection and protection.<sup>13</sup> It is reported that metallic nanoparticles have antibacterial, antioxidant and anticancer effects. Metallic nanoparticles such as titanium oxide, in combination with plant extracts, show anti-breast cancer activity and reduce tumour volume by destroying free radicals.<sup>14</sup>

Studies on the anticancer effects of many plants and nanoparticles have been conducted. These new therapy options appear to be more effective, less expensive, safer, and more widely applicable than their predecessors.<sup>15</sup> These compounds could potentially be harnessed to develop therapeutic strategies that complement conventional remedies in an effort to improve cancer prevention and treatment. The potential for transforming phytochemicals into commercially available pharmaceuticals with cancer prevention and treatment capabilities is substantial.<sup>16</sup>

## 2 Methodology

### 2.1. Plant collection

The *C. cheiri* was collected from various areas in Punjab, Pakistan, it was validated by a taxonomist and submitted with voucher number IMBB.UOL.931-7 to the herbarium bank of the university.

### 2.2. Extraction and fractionation

For preparing the plant extracts, its aerial parts were shade dried for 10 days, crushed into powder using an electromechanical grinder and stored in sterilized zipper plastic bags for further processing. The plant powder (400 grams) was soaked in 600 mL of ethanol and hexane solvents each for two weeks and kept at room temperature. After two weeks, Whatman filter paper was utilized for the filtration of the aqueous extract. Moreover, the aqueous extract was evaporated through rotary evaporation and the dried extract was lyophilized for research purposes.

### 2.3. Phytochemical analysis

The preliminary phytochemical screening of the *n*-hexane and ethanol extracts of *C. cheiri* was performed using standard procedures.<sup>12</sup>

### 2.4. Total phenolic content determination (TPC)

A stock solution was prepared by dissolving the dried plant extracts obtained from ethanol and *n*-hexane in a minute quantity of dimethyl sulphoxide (DMSO) to make dilutions at 1 mg mL<sup>-1</sup> with distilled water. The standard gallic acid (0–6  $\mu$ g mL<sup>-1</sup>) was taken as a reference. Then, 0.5 mL of each extract



was dissolved in 2.25 mL of Folin reagent (10%) and mixed thoroughly. Sodium carbonate solution (7.5%, 2.5 mL) was added and the volume was raised up to 10 mL with distilled water. Then this solution was kept at 37 °C for half an hour. Using a spectrophotometer, the absorbance was measured at 760 nm. Based on the calibration curve, the TPC was determined and it is equivalent to a mg of gallic acid.<sup>17</sup>

## 2.5. Total flavonoid content determination (TFC)

A stock solution was prepared by dissolving the dried plant extracts obtained from ethanol and *n*-hexane in a minute quantity of dimethyl sulphoxide (DMSO) to make dilutions at 1 mg mL<sup>-1</sup> with distilled water. As the standard, the drug catechin was used and 0–100 µg mL<sup>-1</sup> was dissolved in methanol. 0.5 mL of sample was dissolved in 0.15 mL of aluminum chloride solution (10%), 0.15 mL of potassium acetate (0.1 mM) and the volume was raised to 5 mL. The mixture was incubated at room temperature for 40 minutes and the volume was made up to 10 mL with distilled water. Then this solution was kept at 37 °C for half an hour. Using a spectrophotometer, the absorbance was measured at 415 nm. Based on the calibration curve, the TFC was determined and it is equivalent to a mg of catechin.<sup>17</sup>

## 2.6. Determination of antioxidant potential

**2.6.1. DPPH free radical scavenging assay.** For the preparation of stock solutions of the plant extracts (5 mg mL<sup>-1</sup>), DPPH (2-diphenyl-1-picryl-hydroxyl) (0.004%) and ascorbic acid (5 mg mL<sup>-1</sup>) were dissolved in 95% methanol. Then, serial dilutions were made at six different concentrations of 50 µg mL<sup>-1</sup> to 300 µg mL<sup>-1</sup> and of the standard reagents. Freshly prepared DPPH (4 mL) was dissolved in 0.15 mL of each sample and covered with aluminum foil or kept in the dark for half an hour. A control was prepared by dissolving 3 mL of DPPH in 0.1 mL of methanol. Using a spectrophotometer, the absorbance was measured at 517 nm. The percentage inhibition was measured. Ascorbic acid served as the reference standard.<sup>18</sup>

**2.6.2. ABTS scavenging assay.** The standard protocol was followed to determine the ABTS scavenging potential.<sup>19</sup> For this, 20 µL (six concentrations) of the ethanol and *n*-hexane extracts along with the ABTS (180 µL) working solution were integrated discretely in each well of a 96-well plate. Thus, 6 minutes of incubation at room temperature was enough to measure the absorbance for each sample at 734 nm. Here, ascorbic acid was the standard from which the IC<sub>50</sub> values and percentage inhibition were calculated.

**2.6.3. Hydrogen peroxide assay.** The scavenging activity of the plant extracts was estimated using a standard procedure.<sup>20</sup> Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) solution was prepared with phosphate buffer saline (2 mM L<sup>-1</sup> at pH 7.4). Different concentrations of plant extracts (50–300 µg mL<sup>-1</sup>, 0.1 mL) were added with 0.3 mL of PBS and 0.6 mL of hydrogen peroxide solution and kept for 10 minutes at room temperature. The absorbance of the blank and plant samples was measured at 230 nm. Ascorbic acid was used as a standard reagent. Likewise, the percentage inhibition of the plant extracts was evaluated.

## 2.7. Gas chromatography-mass spectrometry (GC-MS) analysis

GC-MS was conducted on an Agilent USA Technologies GC system on a GC-7890B/MS-5977 A model to identify the bioactive chemicals in the *n*-hexane extract of the entire *C. cheiri* plant. The inlet temperature was held at 280 °C by using helium as a carrier gas while maintaining a 1 mL min<sup>-1</sup> flow rate. A 1 µL sample volume was injected into the column (DB 5 MS, 3 cm length, and 0.25 mm diameter by 250 mm thickness). However, the carrier gas that was utilized here was helium. The oven temperature was set to be 50 °C for 1 minute, 25–120 °C for 5 minutes, while a temperature of 250 °C was maintained for the injector port and detector. The runtime was held at 51.133 minutes. However, a calibration was carried out with a comparison of the mass spectrum (molecular fingerprint) of the separated molecule by way of the mass to charge ratio. Finally, the mass spectrum of each chemical was compared using the PubChem libraries.<sup>21</sup>

## 2.8. Synthesis and characterization of TiO<sub>2</sub> nanoparticles

Titanium dioxide nanoparticles were synthesized *via* a hydrothermal method.<sup>22</sup> Titanium dioxide with a molecular weight of 79.88 and sodium hydroxide with a molecular weight of 40 were used. Here, the molar ratio of TiO<sub>2</sub> is 1 M and the mass of the NaOH is calculated by taking 1 M. First, the calculated mass of 1 g of NaOH is taken in a beaker containing 25 mL of distilled water. It was stirred for 30 minutes to obtain a clear solution. Then, the calculated mass of 2 g of TiO<sub>2</sub> is added to the above solution. The mixture was stirred vigorously and continuously for 24 hours. The mixture was transferred to an alumina crucible and kept undisturbed for the setting of the sol-gel. Then, it was dried at 50 °C. Finally, it was placed in a furnace at 400 °C for 2 hours for the calcination of the sample. The sample was taken and made into a very fine powder by grinding it with a mortar and pestle for 1 hour to obtain the TiO<sub>2</sub> nanopowder. Further, XRD, SEM analysis and EDX were used to characterize the produced nanoparticles.<sup>23</sup>

## 2.9. Synthesis of the phyto-nano hybrid

*C. cheiri* solution was prepared by dissolving 3 mg of lyophilized *C. cheiri* in 3 mL of DMSO. The *C. cheiri* solution was gradually added to the functionalized TiO<sub>2</sub> NPs with stirring with a magnetic stirrer at 800 rpm for 30 min. The *C. cheiri*-loaded TiO<sub>2</sub> NPs were centrifuged at 6000 rpm for 10 min. The pellet was separated from the supernatant, washed using deionized water, dried at room temperature, and kept at –20 °C.<sup>9</sup>

## 2.10. Animal model

A sample size of 30 female Wistar rats was chosen using the G\*Power 3 program.<sup>22</sup> For the experiment, 40–50 days old Wistar rats were used. Before the induction of DMBA, the animals underwent a two-week acclimatization period. The study was carried out strictly following the guidelines of the institutional animal ethical committee for handling experimental animals and was approved by the Bioethical, Biosafety



Table 1 Experimental treatment groups with the number of rats in each group<sup>a</sup>

Groups	Treatment	Number of rats	Induction
A (Placebo)	Normal saline	5	Control
B (Induced)	DMBA + olive oil + normal saline	5	Induced female rat
C (T1)	Doxorubicin	5	Standard drug
D (T2)	<i>C. cheiri</i>	5	<i>C. cheiri</i>
E (T3)	TiO <sub>2</sub> nanoparticles	5	TiO <sub>2</sub> nanoparticles
F (T4)	Phyto-nano hybrid	5	<i>C. cheiri</i> + TiO <sub>2</sub> nanoparticles hybrid

<sup>a</sup> Doxorubicin (20 mg per kg bodyweight) for 28 days, *C. cheiri* for 28 days (100 mg per kg bodyweight), TiO<sub>2</sub> for 28 days (50 mg per kg bodyweight), phyto-nano hybrid (50 mg per kg bodyweight).

and Biosecurity Committee (BBBC) of the Institute of Molecular Biology and Biotechnology at the University of Lahore with Ref No: CRiMM/23/Research/33.

**2.10.1. Experimental design.** Six groups of three Wistar rats were created randomly. Group A (the control) received only normal saline, water and regular food. It was decided to induce breast cancer chemically using DMBA.<sup>24</sup> A single dosage of 10 mg of DMBA dissolved in normal saline (0.5 mL) and sesame oil (0.5 mL) was administered in mammary fat pads twice in a week in groups B, C, D, E and F for 2 weeks. After 8 weeks, tumor development was seen in every Wistar rat. After it was determined that all of the Wistar rats had mammary tumors, Groups C, D, E and F received treatment for 4 weeks with aqueous DOX solution (3 mg mL<sup>-1</sup>) in group C (T1), 2 mL of aqueous solution of *C. cheiri* (15 mg mL<sup>-1</sup>) in group D (T2), 2 mL of TiO<sub>2</sub> solution (7.5 mg mL<sup>-1</sup>) in group E (T3) and the phyto-nano hybrid (7.5 mg mL<sup>-1</sup>) in group F (T4), as shown in Table 1. Through cervical dislocation, the animals were rendered unconscious and sacrificed after four weeks of treatment. Blood was collected for hematological analysis and plasma isolation. Histopathology was performed.

### 2.11. Tumor volume

The tumor volume was calculated using the method suggested by Geran.<sup>24</sup> A Vernier caliper was used to perform the measurement.

### 2.12. Blood sample collection

Using 27 gauge needles, 3 mL of blood was drawn from the heart of the rat by an experienced lab assistant and collected in EDTA vials (1.5 mL for EDTA and 1.5 mL for serum tubes). Blood samples were sent immediately for hematological analysis in an ice box.

### 2.13. MicroRNA extraction and quantification

Plasma was isolated using a two-step centrifugation method and stored at -20 °C for further processing. After that, 200 µL of plasma was added to 600 µL of TRIzol with 10 minutes of incubation on ice, followed by 10 minutes of centrifugation at 12 000g and 4 °C. With an addition of 200 µL of chloroform and manual vibration 10 times, a further 10 minutes of incubation on ice followed along with 10 minutes of centrifugation at 12 000g and 4 °C. After discarding the supernatant, 1 mL of freshly prepared 75% ethanol was added in every tube, followed by 15

Table 2 MicroRNA Primer Sequences

Primer name	Mature sequence (5'-3')
miR-205	CCTTAAAGGCTAAGATTTTA
miR-16	CGCAGTAGCAGCACGTA

minutes of centrifugation at 12 000g and 4 °C. Next, the ethanol was discarded and the cap of the centrifuge tube was removed to carry out natural air-drying. Finally, 30 µL of RNase free water was added for dissolving the RNA. The optical density (OD) values and the purity of the RNA were measured.<sup>25</sup>

### 2.14. Primer designing

To quantify the selected miRNAs, RNA primers were used and designed according to the protocol in ref. 26 (Table 2).

### 2.15. Reverse transcription

Further processing of the mixture was carried out for the synthesis of cDNA using the Thermo Scientific™ RevertAid™ first strand cDNA synthesis kit (cat no. K1622). Moreover, the recommended protocol used, 1 µL of random hexamer and 5 µg total of RNA, and DEPC water was added until the total volume was 12 µL. Additionally, the mixture was incubated at 65 °C for 5 minutes and it was chilled on ice. M-MuLV Revert Aid Reverse Transcriptase enzyme (200 U), dNTPs mix (10 mM), and 1× RT buffer were added and DEPC water was added until the total volume reached 20 µL. Lastly, the solution was gently mixed while executing reverse transcription with the help of incubation at 70 °C for five minutes, 42 °C for sixty minutes and 25 °C for five minutes.<sup>27</sup>

### 2.16. Real-time PCR

For the quantitative PCR analysis, Maxima SYBR Green/ROX qPCR Master Mix (2X) (Thermo Scientific (Pvt.) Ltd, USA) (cat no. K0221) in a StepOne Plus system (Thermo Fisher Scientific) was used. The qRT-PCR reaction setups were prepared in 0.2 mL sterile tubes by mixing 10 µL of 2X Maxima SYBR Green/ROX qPCR Master Mix fluorescein, 250 nM of each primer set in 1 µL of 10× diluted cDNA with a total volume of 20 µL. Therefore, the cyclic conditions set for the STEP ONE PLUS Real-Time System were: annealing at primer precise temperatures between 55–60 °C for 60 s with extension at 72 °C for 30 s and 95 °C for 10 minutes followed by 40 heating cycles at 95 °C for



15 s. Hence, all the qRT-PCR experiments were carried out in replicates with a quantification basis of the threshold cycle estimation ( $\Delta C_t$  value). Normalization of the raw data was done through subtraction of the  $C_t$  value of the normalizer mir-16 from the  $C_t$  value of the target microRNA and target gene prior to the analysis.<sup>27</sup>

### 3 Results

#### 3.1. Qualitative phytochemical analysis

The qualitative phytochemical screening revealed the presence of phenol flavonoids, alkaloids, tannins, steroids and terpenoids in the *n*-hexane and ethanol extracts of *C. cheiri* (Table 3).

#### 3.2. Phytochemical evaluation of plant extracts

**3.2.1. Determination of total flavonoid and phenolic content.** Furthermore, the TPC in the ethanol and *n*-Hexane extracts of *C. cheiri* was  $478.80 \pm 4.23$  mg gallic acid equivalent per gram and  $765.45 \pm 4.64$  mg gallic acid equivalent per gram, respectively. The TFC in the ethanol and *n*-hexane extracts of *C. cheiri* were  $53.34 \pm 2.13$  mg catechin equivalent per gram and  $59.19 \pm 1.24$  mg catechin equivalent per gram, respectively.

**3.2.2. Antioxidant potential of the plant extracts.** *In vitro*, the scavenging capacity of the *C. cheiri* ethanolic and *n*-hexane extracts was predicted, as well as that of a reference reagent (ascorbic acid).

**3.2.3. DPPH radical scavenging assay.** The determination of the antioxidant activity of the ethanolic and *n*-hexane extracts of *C. cheiri* was done by calculating the percentage suppression of free radicals, as shown in (Fig. 1a). The *n*-hexane extract had the highest antioxidant activity ( $IC_{50} = 30.80 \mu\text{g mL}^{-1}$ ), whereas the ethanol extract had a lower activity ( $IC_{50} = 74.12 \mu\text{g mL}^{-1}$ ) compared to the standard reagent ( $IC_{50} = 17.98 \mu\text{g mL}^{-1}$ ).

**3.2.4. ABTS radical scavenging assay.** Thus, Fig. 1b shows the antioxidant activity of the ethanolic and *n*-hexane extracts of *C. cheiri* assessed using the free radical percentage inhibition. In contrast to the standard reagent, the ethanol extract demonstrated a comparatively lower antioxidant activity ( $IC_{50} = 25.8 \mu\text{g mL}^{-1}$ ), whereas the *n*-hexane extract exhibited the highest antioxidant activity ( $IC_{50} = 34.5 \mu\text{g mL}^{-1}$ ).

**3.2.5. Hydrogen peroxide free radical ( $H_2O_2$ ) scavenging activity.** The antioxidant activity of the ethanolic and *n*-hexane extracts of *C. cheiri* was assessed by quantifying the percentage inhibition of free radicals, as shown in Fig. 1c. The ethanol extract demonstrated the highest level of antioxidant activity, having an  $IC_{50}$  value of  $80.42 \mu\text{g mL}^{-1}$ , while the *n*-hexane extract showed lower antioxidant activity with an  $IC_{50}$  value of  $102.23 \mu\text{g mL}^{-1}$ . In contrast, the standard reagent had an  $IC_{50}$  of  $50.24 \mu\text{g mL}^{-1}$ .

#### 3.3. GC-MS analysis of *Cheiranthus cheiri*

A reliable GC-MS technique for the identification of the constituents of volatile matter, such as long obtained branched hydrocarbons, esters, acids and alcohols was used. On the basis of the

Table 3 Phytochemical screening of the crude extracts of the medicinal plant *C. cheiri*<sup>a</sup>

Sr. no.	Phytochemical constituents	Ethanol extract of <i>C. cheiri</i>	<i>n</i> -Hexane extract of <i>C. cheiri</i>
1	Flavonoids	+	+
2	Phenols	+	+
3	Alkaloids	+	+
4	Tannins	+	+
5	Steroids	+	+
6	Terpenoids	+	—
7	Saponins	—	+

<sup>a</sup> (+) Indicates the presence and (—) indicates the absence of phytochemical compounds.




Fig. 1 Antioxidant potential of the ethanol and *n*-hexane extracts of *C. cheiri* and the standard, ascorbic acid. (a) DPPH scavenging activity, (b) ABTS radical scavenging assay, and (c) hydrogen peroxide scavenging activity. All results are in triplicate, are significant and have a  $p$ -value  $\leq 0.05$ .





Table 4 Phytocompounds found in *n*-hexane extract of *C. cheiri* using the GC-MS method

No. of peaks	List of compounds	Molecular weight	Formula	Retention time	Area sum%	Class of phytochemical
1	Cyclohexene, 4-methylene-1-(1-methylethyl)-	136	C <sub>10</sub> H <sub>16</sub>	11.123	0.14	Terpenoid
2	3-Cyclohexene-1-ol, 4-methyl-1-(1-methylethyl)-, ( <i>R</i> -)	154	C <sub>10</sub> H <sub>18</sub> O	16.03	0.16	Terpineol
3	Octanoic acid, ethyl ester	172	C <sub>10</sub> H <sub>20</sub> O <sub>2</sub>	16.194	0.05	Fatty acid ester
4	Dodecane	170	C <sub>12</sub> H <sub>26</sub>	16.294	0.09	Alkane
5	Benzaldehyde, 4-(1-methylethyl)-	148	C <sub>10</sub> H <sub>10</sub> O	17.388	0.06	Benzaldehyde
6	Thymol	150	C <sub>10</sub> H <sub>14</sub> O	18.285	0.47	Phenol
7	1,3-Benzodioxole, 5-(1-propenyl)-, ( <i>Z</i> )-	162	C <sub>10</sub> H <sub>10</sub> O <sub>2</sub>	18.385	0.09	Benzodioxole
8	Propanoic acid, 2-methyl-, 3-hydroxy-2,4,4-trimethylpentyl ester	216	C <sub>12</sub> H <sub>24</sub> O <sub>3</sub>	20.028	0.05	Carboxylic acid
9	Copaene	204	C <sub>15</sub> H <sub>24</sub>	20.231	0.07	Sesquiterpene
10	Benzene, 1,2-dimethoxy-4-(2-propenyl)-	178	C <sub>11</sub> H <sub>14</sub> O <sub>2</sub>	20.484	0.05	Dimethoxybenzene
11	Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1 <i>R</i> -(1 <i>R</i> *,4 <i>Z</i> ,9 <i>S</i> *)]-	20411	C <sub>15</sub> H <sub>24</sub>	21.15	0.08	Terpenoid
12	Octanoic acid, 2-ethoxyethyl ester	216	C <sub>12</sub> H <sub>24</sub> O <sub>3</sub>	21.632	0.13	Benzoidic acid ester
13	1,3-Benzodioxole, 4-methoxy-6-(2-propenyl)-	192	CH <sub>12</sub> O <sub>3</sub>	22.8	0.56	Benzodioxole
14	Asarone	208	C <sub>12</sub> H <sub>16</sub> O <sub>3</sub>	23.221	0.63	Phenylpropanoid
15	Dodecanoic acid, ethyl ester	228	C <sub>14</sub> H <sub>28</sub> O <sub>2</sub>	23.805	0.22	Fatty acid ester
16	Methyl tetradecanoate	242	C <sub>15</sub> H <sub>30</sub> O <sub>2</sub>	26.179	0.1	Fatty acid methyl ester
17	Tetradecanoic acid	228	C <sub>14</sub> H <sub>28</sub> O <sub>2</sub>	26.923	0.1	Long chain fatty acid
18	Tetradecanoic acid, ethyl ester	256	C <sub>16</sub> H <sub>32</sub> O <sub>2</sub>	27.736	0.38	Fatty acid ester
19	3-Tetradecanone	212	C <sub>14</sub> H <sub>28</sub> O	29.771	0.3	Alkane
20	Hexadecanoic acid, methyl ester	270	C <sub>17</sub> H <sub>34</sub> O <sub>2</sub>	31.83	0.64	Fatty acid methyl ester
21	Hexadecanoic acid, ethyl ester	284	C <sub>18</sub> H <sub>36</sub> O <sub>2</sub>	34.72	1.91	Fatty acid ethyl ester
22	3-Hexadecanone	240	C <sub>16</sub> H <sub>32</sub> O	38.555	0.37	Ketone
23	9,12-Octadecadienoic acid, methyl ester	294	C <sub>19</sub> H <sub>34</sub> O <sub>2</sub>	40.49	1	Linoleic acid
24	9,12-Octadecadienyl chloride, ( <i>Z,Z</i> )-	298	C <sub>18</sub> H <sub>31</sub> ClO	40.939	4.81	Alkyl chloride
25	9,12,15-Octadecatrienoic acid, methyl ester, ( <i>Z,Z,Z</i> )-	292	C <sub>19</sub> H <sub>32</sub> O <sub>2</sub>	45.557	3.82	Fatty acid methyl ester
26	9,12-Octadecadienoic acid, ethyl ester	308	C <sub>20</sub> H <sub>36</sub> O <sub>2</sub>	46.22	16.49	Fatty acid ethyl ester
27	Ethyl 9,12,15-octadecatrienoate	306	C <sub>20</sub> H <sub>34</sub> O <sub>2</sub>	53.248	2.5	Fatty acyls, linoleic acid
28	Stearic acid, 2-hydroxy-1-methylpropyl ester	356	C <sub>22</sub> H <sub>44</sub> O <sub>3</sub>	54.659	0.75	Fatty acid ester
29	<i>cis</i> -11-Eicosenoic acid	310	C <sub>20</sub> H <sub>38</sub> O <sub>2</sub>	56.69	2.23	Fatty acyl
30	Methyl 9-eicosenoate	324	C <sub>21</sub> H <sub>40</sub> O <sub>2</sub>	58.28	4.55	Ester
31	<i>cis</i> -11-Eicosenoic acid, methyl ester	324	C <sub>21</sub> H <sub>40</sub> O <sub>2</sub>	58.486	17.77	Fatty acid ester
32	9,12-Octadecadienoic acid ( <i>Z,Z</i> )-, 2,3-dihydroxypropyl ester	354	C <sub>21</sub> H <sub>38</sub> O <sub>4</sub>	58.896	0.57	Monoacylglycerol
33	Butyl 9,12,15-octadecatrienoate	334	C <sub>22</sub> H <sub>38</sub> O <sub>2</sub>	60.76	0.87	Fatty acyl
34	Stearic acid, 2-hydroxy-1-methylpropyl ester	356	C <sub>22</sub> H <sub>44</sub> O <sub>3</sub>	61.858	2.96	Fatty acid ester
35	Ethyl 13-docosenoate	366	C <sub>24</sub> H <sub>46</sub> O <sub>2</sub>	61.943	0.43	Fatty acid ethyl ester
36	<i>cis</i> -13-Eicosenoic acid	310	C <sub>20</sub> H <sub>38</sub> O <sub>2</sub>	62.189	0.34	Fatty acyl
37	9,12,15-Octadecatrienoic acid, 2,3-dihydroxypropyl ester, ( <i>Z,Z,Z</i> )-	352	C <sub>21</sub> H <sub>36</sub> O <sub>4</sub>	64.516	1.35	Glycerophospholipid
38	<i>Z</i> -(13,14-Epoxy) tetradec-11-nen-1-ol acetate	268	C <sub>16</sub> H <sub>28</sub> O <sub>3</sub>	66.43	19.83	Fatty acyl
39	<i>cis</i> -13-Docosenyl chloride	356	C <sub>22</sub> H <sub>41</sub> ClO	68.087	4.49	Fatty acyl chloride
40	( <i>F</i> )-13-Docosenoic acid	338	C <sub>22</sub> H <sub>42</sub> O <sub>2</sub>	68.455	0.55	Fatty acyl
41	Dodecanoic acid, 1,2,3-propanetriyl ester	638	C <sub>39</sub> H <sub>74</sub> O <sub>6</sub>	69.702	0.76	Triacylglycerol
42	$\gamma$ -Tocopherol	416	C <sub>28</sub> H <sub>48</sub> O <sub>2</sub>	72.204	1.45	Phenol
43	$\beta$ -Tocopherol	416	C <sub>28</sub> H <sub>48</sub> O <sub>2</sub>	74.631	4.89	Phenol lipid
44	Heptacosane	380	C <sub>27</sub> H <sub>56</sub>	75.105	0.94	Alkane
45	Cholestane-3,5-diol,5-acetate, (3 $\beta$ ,5 $\alpha$ )-	446	C <sub>29</sub> H <sub>50</sub> O <sub>3</sub>	76.12	1.23	Diterpene
46	Campesterol	400	C <sub>28</sub> H <sub>48</sub> O	76.34	4.33	Phytosterol
47	$\gamma$ -Sitosterol	414	C <sub>29</sub> H <sub>50</sub> O	76.48	4.28	Stigmastane




Fig. 2 Phytochemical characterization of *C. cheiri* by GCMS analysis.

antioxidant activities, the *n*-hexane extract was selected for GC-MS analysis. The analysis of the GC-MS for *n*-hexane extract of *C. cheiri* yielded 48 prominent peaks with concentration, molecular weight, molecular formula, and retention time (Table 4). The GC-MS analysis of the *C. cheiri* *n*-hexane extract showed 48 prominent peaks with diverse retention time and area sums ranging from 11.123 to 75.105 minutes and 0.05 to 19.83, respectively. Heptacosane had the longest retention time of 75.105 minutes and, while cyclohexene, 4-methylene-1-(1-methylethyl) had the shortest retention time within the range of 11.123 minutes. *Z*-(13,14-Epoxy) tetradec-11-en-1-ol acetate was found to be present in the highest concentration (19.83) in the *C. cheiri* *n*-hexane extracts (Fig. 2).

### 3.4. XRD analysis

The TiO<sub>2</sub> nanoparticle crystal structure was studied using XRD. Many diffraction peaks are present in the TiO<sub>2</sub> nanoparticle XRD patterns, as illustrated in Fig. 3. The scanning range goes from  $2\theta$  to 80°. Sharp peaks were located at  $2\theta = 25.12^\circ$ ,  $27.68^\circ$ , and  $39.62^\circ$  and coincide with *hkl* values of (101), (110), and (112), respectively, which correlates with the tetragonal phase and matches JCPDs (card no 84-128) as well as JCPDs card no 01-073-1764 (Table 5). The findings reveal that TiO<sub>2</sub> has an anatase (tetragonal) crystalline shape with parameters of  $a = b = 3.789603$  and  $c = 9.516015$ , as shown in Fig. 3. We can determine the average length of the crystalline nanoparticles using the Debye-Scherrer equation.

$$D = \frac{K\lambda}{\beta \cos \theta}$$

$\beta$  represents the full width at half-maximum (FWHM) of the relevant peak,  $\lambda$  is the wavelength and  $2\theta$  is the Bragg diffraction angle, while  $D$  is utilized to indicate the crystal form of the nano powder.




Fig. 3 XRD analysis of the TiO<sub>2</sub> nanoparticles.

Table 5 TiO<sub>2</sub> nanoparticle XRD patterns. The diffraction angles and data for the sharp peaks representing the shape and length of the nanoparticles

$2\theta$	FWHM ( $^\circ$ )	<i>d</i> -spacing	Cross ponding plane ( <i>hkl</i> )	Crystallite size (nm)
25.12448	0.6396	1.329	(101)	13.29
27.6830	2.9862	2.862	(110)	28.62
39.6279	3.6258	2.435	(112)	24.32






Fig. 4 SEM analysis of the TiO<sub>2</sub> nanoparticles. The SEM image clearly exhibits the morphology of the TiO<sub>2</sub> nanoparticles which is a spherical agglomeration that is homogenously distributed through the entire surface.

### 3.5. SEM analysis

The creation of TiO<sub>2</sub> nanoparticles was confirmed through SEM analysis, which is illustrated in Fig. 4, and the shape and structure is demonstrated on the micro-meter scale. The scale bar in the SEM micrograph represents 1 μm. The SEM image clearly exhibits that the morphology of the TiO<sub>2</sub> nanoparticles is a spherical agglomeration and that they are homogenously distributed through the entire surface. The structure of the prepared nanoparticles of TiO<sub>2</sub> accumulates within the aqueous suspension (Fig. 4). The formation of an agglomeration appears to be due to the fragility of the TiO<sub>2</sub> nanoparticles and their small nanoparticular shape. Thus, the nanoparticles have the tendency to bind together until the particles become slightly more stable.

### 3.6. EDX analysis

The energy dispersive X-ray spectroscopy technique was applied to identify the chemical composition of the prepared nanoparticles and to obtain information about the elemental composition of every single element in the samples. Fig. 5 shows the EDX chemical composition analysis of the specimen. The spectrum indicates the existence of pure titanium and oxygen peaks in the specimen being examined. The weight percentages and atomic percentages of Ti and O are 19.91% and 64.41%, and 7.6% and 73.35%, respectively, as given in the inset table. Some impurity peaks are seen in the spectrum and the atomic and weight percentages of Rb, Cl, and Cu are 0.13% and 0.46%, 0.06% and 0.63%, and 0.89% and 0.19%, respectively.




Fig. 5 EDX spectrum of the TiO<sub>2</sub> nanoparticles. Peaks representing pure titanium and oxygen are present in the specimen.



The existence of pure oxygen and titanium in the EDX analysis confirmed the creation of pure TiO<sub>2</sub> nanoparticles.

### 3.7. Animal body weight study

The body weight of the rats in the DMBA treated group was found to increase with an increase in time duration of the experiment. However, after treatment with the whole plant extract nanoparticles and the standard drug doxorubicin, a substantial reduction ( $p < 0.05$ ) in the bodyweight was observed compared to the group that received DMBA alone.

### 3.8. Complete blood count

A significant difference was observed between the control, DMBA-induced and treatment groups. The difference between the breast cancer and the treatment groups was significant in terms of the Hb, HCT, and MCV parameters ( $p < 0.05$ ). Also, there was a moderate difference between the DMBA and treatment groups in the MPV and MCH parameters ( $p < 0.05$ ). Meanwhile, there was a minimal difference between the groups in terms of the MCHC parameter and the WBC and RBC counts. There was no significant difference found in the platelet, lymphocyte, monocyte, and basophil counts between these groups ( $p > 0.05$ ) (Table 6).

### 3.9. Histopathology of the mammary glands

Histological examination of a given section of the mammary glands reveals a skin covered piece of tissue. The epidermis is unremarkable, the underlying dermis reveals benign skin appendages and the deep dermis reveals fibro collagenous tissue and mature adipose tissue. No granulomas are seen and there is no evidence of malignancy (Fig. 6a). Histological examination of a given section of the mammary glands reveals features of non-invasive cystic carcinoma and formation of tumour embolus, composed of malignant epithelial cells with hyper chromatic nuclei, a high N/C ratio and scanty clear to eosinophilia cytoplasm and inconspicuous nucleoli. The intervening stroma reveals fibrosis, congested blood vessels and adipose tissue infiltrated by mild chronic inflammatory cell infiltrate (Fig. 6b). Histopathology reveals chronic inflammation in the dilated




Fig. 6 Histopathological analysis of breast tissues. (a) The control group reveals mature adipose tissue along with a collection of lymphoid tissue. No evidence of granulomatous or a neoplastic process are noted. (b) The DMBA-induced untreated group has chronic inflammation in the dilated ducts and evidence of tumor embolus formation. (c) The DMBA-induced doxorubicin treated group reveals cystic changes, inflammatory cells and elongated cells. (d) The DMBA-induced *C. cheiri* treated group reveals cystic changes. (e) The DMBA-induced TiO<sub>2</sub> treated group reveals cystic changes, inflammatory cells and elongated cells. (f) The DMBA induced phyto-nano hybrid treated group reveals a mature adipose tissue along with a collection of lymphoid tissue. Inflammatory cells are seen.

ducts (Fig. 6c). Histopathology also reveals cystic changes (Fig. 6d) and mature adipose tissue along with collection of lymphoid tissue. Inflammatory cells are also seen. No evidence of granulomatous or a neoplastic process was found (Fig. 6e). The mature adipose tissue and a collection of lymphoid tissue have been seen. Inflammatory cells are also seen (Fig. 6f).

Table 6 Hematological parameters before and after treatment in breast cancer<sup>a</sup>

Hematological parameters	Normal range	Control	DMBA treated	T1 (Dox)	T2 ( <i>C. cheiri</i> )	T3 (TiO <sub>2</sub> )	T4 (phyto-nano hybrid)
Hb (g dL <sup>-1</sup> )	11.7–14	14.9 ± 0.01	19.1 ± 0.01	17.1 ± 0.02	18.3 ± 0.05	15.2 ± 0.01	12.9 ± 0.01
RBC (× 10 <sup>6</sup> /μL)	5.1–6.6	7.61 ± 0.01	10.2 ± 0.005	9.1 ± 0.05	9.5 ± 0.05	8.4 ± 0.05	8.61 ± 0.01
HCT (%)	30–45	42.07 ± 0.06	59.1 ± 0.05	55 ± 0.050	57.1 ± 0.05	53 ± 0.06	43.08 ± 0.06
MCV (fL)	60–72	55.03 ± 0.05	56.9 ± 0.05	57 ± 0.06	57 ± 0.05	55 ± 0.05	56.12 ± 0.05
MCH (pg)	20–24	19.06 ± 0.05	18.9 ± 0.05	18 ± 0.07	18.1 ± 0.06	19 ± 0.05	20.08 ± 0.05
MCHC (g dL <sup>-1</sup> )	32–35	34 ± 0.04	33 ± 0.04	32 ± 0.05	32.5 ± 0.01	31 ± 0.06	31 ± 0.04
PLT (× 10 <sup>3</sup> /μL)	160–462	983 ± 0.05	1099 ± 0.50	999 ± 0.1	1090 ± 0.5	995 ± 0.01	999 ± 0.05
WBC (× 10 <sup>3</sup> /μL)	3.6–7.2	18.17 ± 0.01	13.7 ± 0.01	14.5 ± 0.01	14 ± 0.07	15 ± 0.01	16.42 ± 0.01
Neutrophils (%)	27–74	10.1 ± 0.05	17.07 ± 0.06	16 ± 0.01	16.1 ± 0.05	15 ± 0.02	9.21 ± 0.05
Lymphocytes (%)	16–70	9.1 ± 0.01	8.3 ± 0.05	8.5 ± 0.05	8.5 ± 0.03	8.8 ± 0.01	9.1 ± 0.01
Monocytes (%)	0–3	2 ± 0.05	2 ± 0.05	2.2 ± 0.01	2.5 ± 0.2	2.9 ± 0.05	2 ± 0.05
Eosinophil (%)	0–3	2.06 ± 0.1	2.03 ± 0.07	2.21 ± 0.01	2.4 ± 0.05	2 ± 0.01	2.06 ± 0.1

<sup>a</sup> The values are the mean ± SD (standard deviation).  $p$ -Values are significant at  $<0.05$ .



### 3.10. miR-205 expression in breast cancer rats

Fold change expression of miR-205 in the DMBA-induced plasma of the rats was downregulated as compared to the control. But after treatment with *C. cheiri*, TiO<sub>2</sub>, doxorubicin and the phyto-nano hybrid, a significant difference was observed. Fold change expression in the plasma of the doxorubicin treated rats was slightly upregulated. In the nano-particles and plant treatment group, microRNA expression was upregulated and it is highly upregulated with the treatment of the phyto-nano hybrid (Fig. 7).

MicroRNA expression analysis showed a statistically significant decrease in levels of miR-205 in the plasma of a breast cancer rat model compared to the control ( $p < 0.05$ ). After treatment with the phyto-nano hybrid, a statistically significant increase in the expression of miR-205 was observed in the breast cancer induced rat models compared to the rat model without any treatment ( $p < 0.05$ ).

## 4 Discussion

Breast cancer is a primary cause of death for women worldwide due to its aggressive invasion process, its early metastasis resistance to chemotherapeutic treatments, and its high mortality rates. Because traditional chemotherapeutic medicines influence the entire body system *via* the blood, there can be several systematic adverse effects, including tissue damage and gastrointestinal discomfort. Plants have been used as treatments for thousands of years across various civilizations.<sup>20</sup> Thus, apart from treatment with chemotherapy and radiotherapy, there should be some natural way to treat breast cancer. The discovery and development of innovative pharmaceutical medications derived from medical plants has a substantial impact on human well-being by treating a variety of ailments. Folk medicine uses *C. cheiri* for several therapeutic applications. The growth of pathogenic bacteria is inhibited by

secondary metabolites, such as flavonoids, alkaloids, phenolic compounds, and steroids.<sup>24</sup> This current phytochemical screening of the *n*-hexane and ethanolic extracts of the whole *C. cheiri* plant exposed the presence of flavonoids, tannins, terpenoids, steroids, glycosides, and phenolic compounds. The secondary metabolites were shown to have pharmacological characteristics. For example, tannins are anti-cancer and anti-inflammatory chemicals; flavonoids are anti-inflammatory and antioxidant compounds; and saponins are antibacterial substances which decrease blood cholesterol.<sup>28</sup> Therefore, the total phenolic content of the ethanolic and hexane *C. cheiri* extracts was estimated to be 478.80 mg gallic acid equivalent per gram and 765.65 mg gallic acid equivalent per gram, correspondingly. The overall phenolic contents of the same extracts were calculated to be 53.34 mg catechin equivalent per gram and 59.19 mg catechin equivalent per gram, respectively. According to earlier studies, medicinal plants contain a high concentration of phenolics as well as flavonoids. Hence, it was found that extracts of *C. cheiri* comprised more total phenols than flavonoids.<sup>29</sup>

Plants are capable of preventing oxidative damage with growth and thus can moderate stress. Enzymatic and non-enzymatic mechanisms protect tissues from activated oxygen species, which can be caused by environmental stressors such as cold, dryness, and air pollution.<sup>30</sup> The results of this study support the use of DPPH, NO, and H<sub>2</sub>O<sub>2</sub> models to investigate the oxidant scavenging capability of *C. cheiri*. The ethanolic extract showed positive antioxidant activity in both the NO model, with an IC<sub>50</sub> of  $15.70 \pm 0.024 \mu\text{g mL}^{-1}$ , and in the DPPH model, with an IC<sub>50</sub> of  $17.98 \pm 0.04 \mu\text{g mL}^{-1}$ , values which are comparable to the corresponding standard, ascorbic acid. In comparison, the *n*-hexane extract exhibited the lowest antioxidant capacities in NO (IC<sub>50</sub>  $24.08 \pm 0.024$ ) and DPPH (IC<sub>50</sub>  $30.80 \pm 0.024$ ). At the same percentage, the H<sub>2</sub>O<sub>2</sub> model demonstrated modest activity, reflected in an IC<sub>50</sub> value of  $57.59 \pm 0.01$




Fig. 7 Graphical representation of the miR-205 quantification analysis. (a) miR-205 is downregulated in the plasma of breast cancer rats compared to the control. (b) MicroRNA is slightly upregulated in the standard treatment but the expression is significantly upregulated in the phyto treatment, nano treatment and phyto-nano hybrid treatment groups. The y-axis denotes the plasma fold change expression of miR-205 normalized to miR-16 as a referenced gene.

$\mu\text{g mL}^{-1}$ . The differences in the antioxidant assay results demonstrate that the best antioxidant activities depend upon their comparative efficacy. The presence of the NO, DPPH and  $\text{H}_2\text{O}_2$  radicals may account for the observed disparities.<sup>31</sup> Therefore, biological antioxidant assays were performed to evaluate the effectiveness of the biologically active compounds present in the ethanol and *n*-hexane extracts. This was done by comparison of the outcomes of the DPPH, NO, and  $\text{H}_2\text{O}_2$  free radical scavenging activity assays based on the nature of compounds present in the extracts.<sup>32</sup>

Medicinal chemistry involves using convenient analytical techniques such as GCMS for detecting complex mixtures of phytocompounds based on solvent polarity.<sup>33</sup> GCMS is utilized for the identification and analysis of the chemicals found in plant samples. In our study, 42 phytocompounds were identified in the *n*-hexane extract through GCMS analysis. This technique is vital for phytochemical research along with chemotaxonomy investigations for medicinal plants with biologically active constituents. Thus, the treatment of breast cancer with herbal medication is a better approach, but for the delivery of these phytocompounds direct to their target, nanoparticles are the best drug delivery system.<sup>34</sup>

The work of different researchers on nanotechnology compounds with anti-cancer properties has led to advancements in the pharmacotherapeutic field. Nanotechnology is a rapidly growing research field in both the global and national context.<sup>35</sup> A previous study reported  $\text{TiO}_2$  nanoparticles<sup>36</sup> and here the X-ray diffraction (XRD) pattern revealed the presence of  $\text{TiO}_2$  nanoparticles. The morphology revealed in the SEM images clearly shows that the  $\text{TiO}_2$  nanoparticles are a spherical agglomeration and are homogeneously distributed over the entire surface. The FWHM showed that the  $\text{TiO}_2$  nanoparticles were spherical in shape with sizes ranging from 13.29 to 24.32 nm. The EDX profile of the  $\text{TiO}_2$  nanoparticles showed a strong Ti peak. The presence of the O peaks along with the Ti signals suggests that the  $\text{TiO}_2$  nanoparticles were protected with phenolate ions. The spectrum data of XRD pattern of the synthesized  $\text{TiO}_2$  nanoparticles revealed the occurrence of four major peaks. The peaks appeared with  $2\theta$  values that correspond to the (111), (200), (220), and (311) planes of the face-centered cubic (fcc) phase, which are comparable with the standard JCPDS 89-3722. The peak positions shed light on the translational proportion, namely the size and shape of the unit cell, while the peak intensities give details about the electron density inside the unit cell where the atoms are located. The width of the (111) peak was utilized to calculate the average crystallite size using the Scherrer equation.<sup>37,38</sup> Our study confirmed that the scanning range goes from  $2\theta$  to  $80^\circ$ . Sharp peaks were located at  $2\theta = 25.12^\circ, 27.68^\circ$ , and  $39.62^\circ$  and coincide with hkl values of (101), (110), and (112), respectively, which correlates with the tetragonal phase and matches with JCPDS card no 84-1285 as well as JCPDS card no 01-073-1764. The findings reveal that the  $\text{TiO}_2$  has the anatase (tetragonal) crystalline shape with parameters of  $a = b = 3.789603$  and  $c = 9.516015$ . We can determine the average length of the crystalline nanoparticles using the Debye-Scheerer equation. Several studies have shown that plants and nanoparticles can modulate

microRNA expression, which in turn can inhibit the proliferation of breast cancer.<sup>35</sup> Studies have reported that changes in the regulation of microRNAs performs a significant part in the progress, advancement, and promotion of breast cancer, therefore, these microRNAs are essential in controlling the disease. Different microRNAs have been identified which are dysregulated in breast cancer. And these microRNAs play a significant regulation role for several molecular procedures such as invasion, proliferation, metastasis, self-renewal, caspase-mediated cell death, and epithelial-mesenchymal transition. MicroRNAs have the potential to act as both oncogenic and tumor suppressors.<sup>39</sup>

There has been prior reporting of miR-205 downregulation in the triple-negative patient population, and its role as a breast tumor suppressor has also been documented.<sup>40</sup> Although miR-205 has been demonstrated to be either increased or downregulated in breast cancer compared with normal tissue, its breast cancer stem cell expression remains unknown.<sup>41</sup> A study found that miR-205, which directly targets and downregulates erbb receptors, is more abundantly expressed in human breast cancer stem cells than in more differentiated tumor cells.<sup>42</sup> Although it was previously known that miR-205 specifically targets *ERBB3*, research has shown that it also regulates *ERBB2* and *EGFR*. While it appears that *ERBB2* is a direct target of this microRNA, p63, which has already been established to have the potential to regulate *EGFR* transcription, it is responsible for mediating the regulation of *EGFR*.<sup>43</sup> A study found that breast cancers are resistant to Lapatinib and other breast cancer treatments because they express less *ERBB* receptor family members. This suggests that miR-205 may be an important target to improve outcomes in patients with breast cancer who overexpress Her2 and if these cells survived then the tumor will proliferate.<sup>42</sup>

MicroRNA profiling and the molecular features of tumor cells has become research of interest in recent years.<sup>44</sup> The primary objective of our research was to evaluate epigenetic modulation in microRNA expression by phytocompounds, nanoparticles and a phyto-nano hybrid. An *in vivo* study was conducted and cancer was induced using DMBA (7,12-dimethylbenzanthracene). After the confirmation of the cancer by histopathology and hematology techniques, treatment was started with plants, nanoparticles and a phyto-nano hybrid. After the treatment, blood was collected and microRNA expression was quantified using real time PCR. We analyzed the data using a real-time RT-PCR technique with SYBR Green. Our study confirmed that miR-205 was downregulated in the breast cancer sample as compared to the control. It was slightly upregulated in treatment with the standard drug doxorubicin. However, microRNA expression was upregulated in treatment with plant and nanoparticles and it was significantly upregulated in treatment with the phyto-nanohybrid. Thus, our study concluded that the phyto-nano hybrid could be a better approach to treat breast cancer and other diseases.

## 5 Conclusions

Breast cancer affects a large number of women worldwide, yet treating it remains difficult. The *C. cheiri* plant and  $\text{TiO}_2$





nanoparticles have shown anti-tumorigenic properties, but the therapeutic impact of a phyto-nano hybrid on microRNA expression has never been investigated. The present work explored the ability of a chemically modified phyto-nano hybrid to inhibit tumorigenesis as depicted by expression of microRNA-205 in breast cancer. MicroRNA expression was downregulated in breast cancer when compared with a control, but after treatment with *C. cheiri*, TiO<sub>2</sub> and a phyto-nano hybrid, microRNA expression was upregulated significantly. The significant change in microRNA expression before and after treatment demonstrated the therapeutic potential of the tested phyto-nano hybrid against breast cancer.

## Data availability

The data is accessible in the supplementary file provided.

## Author contribution

Samiah Shahid conceptualized and designed the research. Fatima Razzaq, Samiah Shahid and Wajeehah Shahid performed the experimental work, analysed data, and drafted the manuscript. All authors critically reviewed and approved the final draft of the manuscript.

## Conflicts of interest

The authors have no conflicts of interests.

## References

- 1 F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *Ca-Cancer J. Clin.*, 2018, **68**(6), 394–424.
- 2 L. Torre, F. Islami, R. L. Siegel, E. Ward and A. Jemal, Global cancer in women: burden and trends, *Cancer Epidemiol., Biomarkers Prev.*, 2017, **26**(4), 444–457.
- 3 D. M. Anwa, M. El-Sayed, A. Reda, J. Y. Fang, S. N. Khattab and A. O. Elzoghby, Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes, *Expert Opin. Drug Delivery*, 2021, **2**(11), 1609–1625.
- 4 M. A. Taylor, K. Sossey-Alaoui, C. L. Thompson, D. Danielpour and W. P. Schiemann, TGF- $\beta$  upregulates miR-181a expression to promote breast cancer metastasis, *J. Clin. Invest.*, 2013, **123**(1), 150–163.
- 5 F. Ahmed, B. Ijaz, Z. Ahmad, N. Farooq, M. B. Sarwar and T. Husnain, Modification of miRNA Expression through plant extracts and compounds against breast cancer: mechanism and translational significance, *Phytomedicine*, 2020, **68**, 153168.
- 6 K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta C_T$  method, *Methods*, 2001, **25**(4), 402–408.
- 7 G. Mosleh, P. Badr, A. Azadi, Z. Abolhassanzadeh and S. V. Hosseini, Wallflower (*Erysimum cheiri* (L.) Crantz) from past to future, *Res. J. Pharmacogn.*, 2019, **6**(2), 85–95.
- 8 B. Singh, A. M. Ronghe, A. Chatterjee, N. K. Bhat and H. K. Bhat, MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis, *Carcinogenesis*, 2013, **34**(5), 1165–1172.
- 9 P. Sadhukhan P, M. Kundu, S. Chatterjee, N. Ghosh, P. Manna and J. Das J, Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy, *Mater. Sci. Eng., C*, 2019, **100**, 129–140.
- 10 K. K. Vekariya, J. Kaur and K. Tikoo, ER $\alpha$  signaling imparts chemotherapeutic selectivity to selenium nanoparticles in breast cancer, *Nanomed.: Nanotechnol. Biol. Med.*, 2012, **8**(7), 1125–1132.
- 11 H. Jiang, J. Sun, F. Liu, X. Wu and Z. Wen, An immune-related long noncoding RNA pair as a new biomarker to predict the prognosis of patients in breast cancer, *Front. Genet.*, 2022, **13**, 895200.
- 12 M. M. Haque, N. Sultana, S. M. T. Abedin and S. E. Kabir, Phytochemical screening and determination of minerals and heavy metals in the flowers of *Nyctanthes arbor-tristis* L, *Bangladesh J. Sci. Ind. Res.*, 2019, **54**(4), 321–328.
- 13 J. Ye, J. Shi, M. Zhang, Y. Zhang, J. Tao and S. Jiang S, Novel Alhagi maurorum leaves mediated synthesis of titanium nanoparticles for human breast carcinoma applications: a preclinical trial study, *Arch. Med. Sci.*, 2021, **28**, 143345.
- 14 N. A. Al-Shabib, F. M. Husain, F. A. Qais, N. Ahma, A. Khan and A. A. Alyousef AA, Phyto-mediated synthesis of porous titanium dioxide nanoparticles from *Withania somnifera* root extract: broad-spectrum attenuation of biofilm and cytotoxic properties against HepG2 cell lines, *Front. Microbiol.*, 2020, **11**, 1680.
- 15 P. Banthia, L. Gambhir, D. Daga, A. Sharma, N. Kapoor and R. D. Agarwal, Phyto-genic synthesis of metallic nanoparticles: application for breast cancer nanomedicine, *Vegetos*, 2023, **1**(1), 10–19.
- 16 S. Behboodi, F. Baghbani-Arani, S. Abdalan and S. A. Sadat Shandiz, Green Engineered Biomolecule-Capped Silver Nanoparticles Fabricated from *Cichorium intybus* Extract: *In Vitro* Assessment on Apoptosis Properties Toward Human Breast Cancer (MCF-7) Cells, *Biol. Trace Elem. Res.*, 2019, **187**(2), 392–402.
- 17 M. A. Mir, K. Parihar, U. Tabasum and E. Kumari, Estimation of alkaloid, saponin and flavonoid, content in various extracts of *Crocus sativa*, *J. Med. Plants Stud.*, 2016, **4**(5), 171–174.
- 18 V. L. Singleton, R. Orthofer and R. M. Lamuela-Raventos, Analysis of total phenols and other oxidation substrates and antioxidants by means of folin-ciocalteu reagent, in *Methods in Enzymology*, Elsevier, 2001, pp. 152–78.
- 19 S. Sultana and S. Mir, Chemical constituents from the roots of *Trichodesma indicum* (L.), *Eur. J. Pharm. Med. Res.*, 2022, **1**(9), 450–456.
- 20 M. Ebrahimzadeh, F. Pourmorad and S. Hafezi, Antioxidant Activities of Iranian Corn Silk, *Turk. J. Biol.*, 2008, **1**(1), 43–49.





- 21 H. Jaberian, K. Piri and J. Nazari, Phytochemical composition and *in vitro* antimicrobial and antioxidant activities of some medicinal plants, *Food Chem.*, 2013, **1**(1), 237–244.
- 22 M. Hossain and S. Islam, Synthesis of Carbon Nanoparticles from Kerosene and their Characterization by SEM/EDX, XRD and FTIR, *Am. J. Nanosci. Nanotechnol.*, 2013, **1**, 1–52.
- 23 I. Romero, D. L. Garcia-Gonzalez, R. Aparicio-Ruiz and M. T. Morales, Validation of SPME–GCMS method for the analysis of virgin olive oil volatiles responsible for sensory defects, *Talanta*, 2015, (134), 394–401.
- 24 F. Faul, E. Erdfelder, A. Buchner and A. G. Lang, Statistical power analyses using G\*Power 3.1: tests for correlation and regression analyses, *Behav. Res. Methods*, 2009, **41**(4), 1149–1160.
- 25 D. S. Metibemu, O. A. Akinloye, A. J. Akamo, J. O. Okoye, D. A. Ojo and E. Morifi, Carotenoid isolates of *Spondias mombin* demonstrate anticancer effects in DMBA-induced breast cancer in Wistar rats through X-linked inhibitor of apoptosis protein (XIAP) antagonism and anti-inflammation, *J. Food Biochem.*, 2020, **44**, 12.
- 26 A. E. Simoes, D. M. Pereira, J. D. Amaral, A. F. Nunes, S. E. Gomes, P. M. Rodrigues, R. D'Hooge, C. J. Steer, S. N. Thibodeau and P. M. Borralho, Efficient recovery of proteins from multiple source samples after trizol® or trizol® LS RNA extraction and long-term storage, *BMC Genomics*, 2013, **14**, 1–5.
- 27 U. Baykal, Development of a sensitive primer extension method for direct detection and quantification of miRNAs from plants, *PLoS One*, 2024, **15**(3), e0230251.
- 28 H. Jonckheere, J. Anne and E. DeClercq, The HIV-1 reverse transcription (RT) process as target for RT inhibitors, *Med. Res. Rev.*, 2000, **20**(2), 129–154.
- 29 T. S. Richard, A. H. N. Kamdje and F. Mukhtar, Medicinal plants in breast cancer therapy, *J. Med. Plants*, 2015, **1**(1), 19–23.
- 30 E. Lambertini, R. Piva, M. T. H. Khan, I. Lampronti, N. Bianchi and M. Borgatti, Effects of extracts from Bangladeshi medicinal plants on *in vitro* proliferation of human breast cancer cell lines and expression of estrogen receptor  $\alpha$  gene, *Int. J. Oncol.*, 2004, **24**(2), 419–423.
- 31 V. S. Slambrouck, A. Daniel, C. Hooten, S. Brock, A. Jenkins and M. Ogasawara, Effects of crude aqueous medicinal plant extracts on growth and invasion of breast cancer cells, *Oncol. Rep.*, 2007, **17**(6), 1487–1492.
- 32 M. M. Mainasara, M. F. A. Bakar and A. C. Linatoc, Malaysian medicinal plants potential for breast cancer therapy, *Asian J. Pharm. Clin. Res.*, 2018, 101–117.
- 33 M. I. Khan, A. Bouyahya, N. E. L. Hachlafi, N. E. Menyiy, M. Akram and S. Sultana, Anticancer properties of medicinal plants and their bioactive compounds against breast cancer: a review on recent investigations, *Environ. Sci. Pollut. Res.*, 2022, **29**(17), 24411–24444.
- 34 S. S. Kamble and R. N. Gacche, Evaluation of anti-breast cancer, anti-angiogenic and antioxidant properties of selected medicinal plants, *Eur. J. Integr. Med.*, 2019, **25**, 13–19.
- 35 Z. O. Omogbadegun, Medicinal plants-based foods for breast cancer treatment: an ethnobotanical survey and digitization, *Int. J. Med. Aromat. Plants.*, 2013, **1**(8), 137–163.
- 36 R. Mund, N. Panda, S. Nimesh and A. Biswas, Novel titanium oxide nanoparticles for effective delivery of paclitaxel to human breast cancer cells, *J. Nanopart. Res.*, 2014, **22**(12), 2739.
- 37 K. Murugan, D. Dinesh, K. Kavithaa, M. Paulpandi, T. Ponraj and M. S. Alsalmi, Hydrothermal synthesis of titanium dioxide nanoparticles: mosquitocidal potential and anticancer activity on human breast cancer cells (MCF-7), *Parasitol. Res.*, 2016, **115**(3), 1085–1096.
- 38 N. Lagopati, P. V. Kitsiou, A. L. Kontos, P. Venieratos, E. Kotsopoulou and A. G. Kontos, Photo-induced treatment of breast epithelial cancer cells using nanostructured titanium dioxide solution, *J. Photochem. Photobiol.*, A, 2010, **15**(2), 215–223.
- 39 N. Chauhan, A. Dhasmana, M. Jaggi and M. M. Yallapu, miR-205: a potential biomedicine for cancer therapy, *Cells*, 2020, **25**(9), 1957.
- 40 H. Wu and Y. Y. Mo, Targeting miR-205 in breast cancer, *Expert Opin. Ther. Targets*, 2009, **13**(12), 1439–1448.
- 41 I. Plantamura, A. Cataldo, G. Cosentino and M. V. Iorio, miR-205 in Breast Cancer: State of the Art, *Int. J. Mol. Sci.*, 2021, **22**(1), 27.
- 42 A. De Cola, S. Volpe, M. C. Budani, M. Ferracin, R. Lattanzio, A. Turdo, *et al.*, miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance, *Cell Death Dis.*, 2015, **6**(7), e1823.
- 43 Y. Hu, Y. Qiu, E. Yague, W. Ji, J. Liu and J. Zhang, miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer, *Cell Death Dis.*, 2016, (6), e2291.
- 44 H. Wu, S. Zhu and Y. Y. Mo, Suppression of cell growth and invasion by miR-205 in breast cancer, *Cell Res.*, 2009, **19**(4), 439–448.

